Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.

[1]  M. Czader,et al.  Hematological Malignancies , 2013, Methods in Molecular Biology.

[2]  A. Gratwohl,et al.  Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  I. Kerridge,et al.  Pre‐transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[4]  C. D. de Souza,et al.  Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR , 2010, BMC infectious diseases.

[5]  R. Martino,et al.  Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience , 2010, Bone Marrow Transplantation.

[6]  A. Baron,et al.  Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Boeckh,et al.  How we treat cytomegalovirus in hematopoietic cell transplant recipients. , 2009, Blood.

[8]  E. Shpall,et al.  Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies , 2007, Bone Marrow Transplantation.

[9]  C. Carlo-Stella,et al.  Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. , 2005, Experimental hematology.

[10]  M. Nasu,et al.  Real-time PCR assays based on distinct genomic regions for cytomegalovirus reactivation following hematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[11]  S. Riddell,et al.  Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. , 2003, Blood.

[12]  G. Papanicolaou,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  C. Sabin,et al.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.

[15]  I. Sia,et al.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. , 2000, Clinical microbiology reviews.

[16]  R. Fanin,et al.  Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. , 1999, Haematologica.

[17]  C. Katlama,et al.  Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection. , 1996, Antiviral Research.

[18]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.

[19]  D. Weisdorf,et al.  Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. , 1993, Transplantation.

[20]  H. Tilg,et al.  Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[22]  P. Ljungman,et al.  Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. , 1990, The Journal of infectious diseases.

[23]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.